Summit Therapeutics is challenging Merck in oncology with ivonescimab, outperforming Keytruda in NSCLC trials. The biotech's potential success could lead to significant market growth and clinical advancements, but it may take years to match Merck's legacy.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing